|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0070 - 0.0074|
|52 Week Range||0.0070 - 0.0945|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 08, 2016|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - September 18, 2023) - Canntab Therapeutics Limited (CSE: PILL) (OTC Pink: CTABF) (FSE: TBF1) (the "Corporation") announces that the Ontario Securities Commission (the "OSC") has rejected the Corporation's application for a management cease trade order (the "MCTO") dated September 14, 2023, as the Corporation is not viewed as having met all of the criteria for an MCTO.The Corporation filed the MCTO application with the OSC due to an anticipated ...
Canntab Therapeutics Limited (CSE:PILL)(OTCQB:CTABF)(FRA:TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing an update on several matters impacting the Company.